CUTIA-B: Next Day Disclosure Return
CUTIA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
CUTIA-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2023 ANNUAL REPORT
CUTIA-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
CUTIA-B: VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OFCU-40102 (TOPICAL FINASTERIDE SPRAY) IN THE PRCACCEPTED FOR E-POSTER PRESENTATION ATTHE 8TH ANNUAL MEETING OF CHINESE HAIR RESEARCH SOCIETY
CUTIA-B: DATE OF BOARD MEETING
CUTIA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
CUTIA-B: VOLUNTARY ANNOUNCEMENT - DRUG MARKETING AUTHORIZATION APPLICATION FOR CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
CUTIA-B: VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED ONLINE IN THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
CUTIA-B: Next Day Disclosure Return
CUTIA-B: Next Day Disclosure Return
CUTIA-B: Next Day Disclosure Return
CUTIA-B: Next Day Disclosure Return
CUTIA-B: VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PROGRAM UNDERTHE SHARE REPURCHASE MANDATE
CUTIA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
CUTIA-B: VOLUNTARY ANNOUNCEMENT - LAST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION
CUTIA-B: VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC ACCEPTED FOR E-POSTER PRESENTATION AT THE 29TH ANNUAL MEETING OF CSD
CUTIA-B: OPERATIONAL UPDATE FORTHE FIRST QUARTER OF 2024
CUTIA-B: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON 5 JUNE 2024
CUTIA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
No Data
No Data